Size drug makers seize India's vaccine market
Our Honey include polyflora honey, acacia honey, sunflower honey, buckwheat honey, linden honey, vitex honey etc. Our Honey 100% Pure Honey,Mixed-Flowers Honey,Polyfloral Honey,Acacia Honey,Multi-flower Honey,Chaste Honey Easy Food (Jiaxing) Co., Ltd. , https://www.jxeasyfood.com
Indian vaccine manufacturer Bharat Biotech is currently re-pricing its vaccines and announced that once it has developed Phase III clinical trials, the rotavirus vaccine it developed will be available to the government at a low price of US$ 1 per needle. Bharat expects the product will be available within the next three years.
Bharat, based in Hyderabad, India, claimed that pre-clinical trials for the vaccine showed a seroconversion rate of 89.6%, which is better than that of GSK and Merck's similar products.
On June 6th, both GlaxoSmithKline and Merck & Co. announced that they will substantially reduce the price of their rotavirus vaccine to low-income countries. Agence France-Presse reported that the British Prime Minister David Cameron will discuss how to raise at least 225 million pounds for the next four years of immunization programs.
GlaxoSmithKline said that through the coordination of the Global Alliance for Vaccine Immunization (GAVI), the price of rotavirus vaccines will be reduced to US$2.50 per dose for developing countries, and the price cut will be as high as 95%. Merck also said that the price of the rotavirus vaccine will be reduced to $5 per dose, and as long as the dosage reaches about 30 million doses, it will be further reduced to $3.50 per dose. GlaxoSmith's rotavirus vaccine Rotarix is ​​priced at about $49.25 in Western markets.
The Indian market is in short supply
In the Indian market, GlaxoSmith's Rotarix is ​​priced at around US$25, but this vaccine is not included in the government-funded immunization program. It is estimated that about 150,000 children die of rotavirus infection in India alone each year.
In view of this huge unmet medical need, Merck also launched its rotavirus vaccine Rotateq in India in March this year.
Krishna Ella, chairman and general manager of Bharat Biotechnology, said: “The provision of rotavirus vaccine for US$1 once again demonstrates our determination to provide affordable vaccines to the world. The reason why we can successfully reduce vaccine costs is because we are New concepts have been introduced in the research and development of vaccines and innovative production processes, and the public health is always considered as the center."
Bharat expects that the Rotavac vaccine it developed will be approved for marketing in India in 2014 and will be available for prequalification from the World Health Organization (WHO) in 2015 to the relevant UN agencies. The company pointed out that its production capacity is about 300 million doses, and it is ready to supply Rotavac to UNICEF, Pan American Health Organization and other national immunization programs.
Ella said in an interview that Bharat has launched Phase III clinical trials for Rotavac and plans to recruit 8,000 children between the ages of 6 and 14 weeks. As one of the largest tests in India's history, the Rotavac test will monitor children for two to three years. The research cost is as high as 25 to 30 million US dollars.
Other vaccines will also cut prices
At the same time, GAVI announced on June 6 that two other Indian companies, the Serum Institute and Panacea Biotec, also decided to downgrade the price of the GAVI-funded five-price vaccine. "Serum has reduced the price of its five-price vaccine to $1.75 per dose, which is the lowest price on the market. The company also said it will continue to provide the most competitive prices and encourage other manufacturers to take similar cuts. Measures."
Prior to this, Pfizer and GlaxoSmithKline also made a similar commitment to provide GAVI with pneumococcal conjugate vaccine to GAVI through the Advanced Market Commitment for GAVI's expiring countries. This plan is A new funding mechanism that can introduce new drugs into developing countries.
Merck also announced that it will supply GAVI with a low price of US$5 per dose for human papillomavirus (HPV) vaccine, which is 67% lower than the current market price. It is the first time that such a price has been supplied to developing countries.
Given that the Indian government has increased its investment in immunization projects to create more opportunities for the market, both large and small businesses are seizing India's vaccine market.
main clients are come from EU and some other countries. Usually they like the package as iron drums with 290 kgs. However, we have IBC tank also, it can load 1400 kgs for net. Our raw honey purchased from bee keeper directly, so that we can control the quality very well. We can supply different type of honey according to your required parameters and package also.